bluebird bio Inc. (BLUE) announced after the close Tuesday that the National Institutes of Health Recombinant DNA Advisory Committee's completed its public review of the HGB-208 pediatric study protocol for bluebird bio's LentiGlobin BB305 product candidate in beta-thalassemia major. The committee recommended to delay initiation of the study in the United States for one to two years. The stock is now down 8.64 on 12K shares.
bluebird bio declined during the first hour of trade Tuesday, but recovered some ground in the early afternoon. Shares finished down by 1.98 at $186.63. The stock closed near the middle of a 3-week range at the highs of the year.
For comments and feedback: editorial@rttnews.com